It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Alder was following up on a phase-two trial that it had first reported last March, when 31% to 33% of patients (depending on the dose) who received a single intravenous infusion of Alder's anti-CGRP antibody ALD403 enjoyed at least a 75% reduction in migraine days over 12 weeks. After 24 weeks, between 29% and 31% experienced the same reduction, vs. 20% of the control group.
If you're a migraine sufferer, read that again...slowly: a single IV dose of this antibody was effective in reducing migraines for 12-24 weeks during the trial! I'm not exaggerating when I say that this could revolutionize the way migraines are treated.
First, they discovered that injecting CGRP into migraine patients intravenously could induce a migraine attack. Next, a CGRP-blocking antagonist called Telcagepant was developed and it was successful at preventing migraines. However, it was found to cause liver damage and the trial was halted.